linjc16/ctgov huggingface dataset:
Protection Against Visible Light by Dihydroxyacetone in Erythropoietic Protoporphyria

Study Overview
=================
Brief Summary
-----------------
What is the visible light protective effect of dihydroxyacetone in individuals with erythropoietic protoporphyria? This will be tested in this randomized blinded placebo controlled study.

Official Title
-----------------
Protection Against Visible Light by Dihydroxyacetone in Erythropoietic Protoporphyria

Conditions
-----------------
Erythropoietic Protoporphyria

Intervention / Treatment
-----------------
* Other: Dihydroxyacetone
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with erythropoietic protoporphyria At least 18 years of age Obtainment of written informed consent Exclusion Criteria: Pregnant or breastfeeding Use of dihydroxyacetone at the treatment or placebo fields within the last two week Sun exposure of the treatment or placebo fields within the last two week Use of suncreen or other local treatment on the treatment or placebo fields during the study period (two days) Allergy to adhesive bandages, dihydroxyacetone or lotion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dihydroxyacetone<br> | Other: Dihydroxyacetone<br>* Application of 10% dihydroxyacetone (2 mg per square cm skin)<br>Other: Placebo<br>* Application of lotion to the skin (2 mg per square cm skin)<br>|
| Placebo Comparator: Placebo<br> | Other: Dihydroxyacetone<br>* Application of 10% dihydroxyacetone (2 mg per square cm skin)<br>Other: Placebo<br>* Application of lotion to the skin (2 mg per square cm skin)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visible light exposure dose to onset of first skin symptom | Assessed by phototesting | Meassurement one day after dihydroxyacetone application | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in skin color from before treatment to one day after treatment | Assessed by color scale. The color scale is presented in DOI: 10.1111/phpp.12458. It is a seven-point scale to assess skin color from light to dark. We expect that a large change in skin color will give the best effect. | Meassurement of skin color just before dihydroxyacetone application and one day after application. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dihydroxyaceton, Erythropoietic protoporphyria, Light protection, Protoporphyrin IX, Self-tanning, Skin
Role of Irisin/FNDC5 (rs3480) Single Nucleotide Polymorphism in Breast Cancer

Study Overview
=================
Brief Summary
-----------------
Breast cancer is the most frequent cancer in women worldwide. Its incidence is increasing but mortality has decreased in a considerable way due to the combined effect of early detection and improvement in treatment . Irisin is encoded by the FNDC5 gene, whose expression is controlled by the peroxi- some proliferator activated receptor gamma coactivator 1 alpha (PGC-1α). PGC-1α is a transcriptional co-activator which does not bind directly to DNA. Studies indicated that the estrogen-related receptor alpha (ERRα) could be a factor that plays a role in PGC-1α binding to DNA. ERRα is encoded by the ESRRA gene and is an orphan nuclear receptor, which has two domains. One of them allows the interaction with DNA, and the second one with a ligand. The ERRα structure is similar to that of the estrogen receptor alpha (ERα), but this receptor does not bind to natural estrogens. ERRα interacts with a canonical sequence of the estrogen response elements (ERRE). ERRα and ERα could compete with each other to bind to similar DNA elements. Together, ERRα binds to DNA, in complex with PGC-1α, to regulate the activity of genes such as FNDC5 . CA15-3, a high molecular weight glycoprotein (300-450 kDa), is produced by the epithelial ducts and acinic breast cells and is then secreted in milk normally. It has been widely used for the prediction of bone metastases in patients with breast cancer .

Official Title
-----------------
Role of Irisin/FNDC5 (rs3480) Single Nucleotide Polymorphism in Breast Cancer

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Genetic: Genotyping


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: histologically confirmed breast cancer Exclusion Criteria: • History of other tumors.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cases group<br>50 patient of histologically confirmed breast cancer | Genetic: Genotyping<br>* Genotyping of rs 3480 of irisin gene using the Taqman Allelic Discrimination assay technique.<br>|
| control group<br>50 healthy volunteers with no clinical evidence of any neoplastic disorder | Genetic: Genotyping<br>* Genotyping of rs 3480 of irisin gene using the Taqman Allelic Discrimination assay technique.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| find a possible association between irisin gene single nucleotide polymorphism with breast cancer | - find a possible association between irisin gene single nucleotide polymorphism with breast cancer risk and the distribution of its alleles, in relation to many clinical parameters of the cancer group. | 12 months |
Algorithms to Improve the Accuracy of the Echocardiographic Report

Study Overview
=================
Brief Summary
-----------------
This observational study aims to improve the accuracy of the report of the echocardiographic study, making it more consistent with the current international guidelines and reducing the diagnostic mistakes in patients undergoing clinically -indicated echocardiography. The main questions it aims to answer are: can the addition of automated diagnostic algorithms help to improve the overall accuracy of the echocardiographic report?

Official Title
-----------------
IMPlementazione di algoRitmi di Assistenza Alla diagnOsi in un Software di Refertazione Computerizzato Che Valuta Anche l'Accuratezza Dell'Esame ECOcardiografico

Conditions
-----------------
Echocardiography

Intervention / Treatment
-----------------
* Device: COMPACS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Having undergone a clinically-indicated echocardiographic study Exclusion Criteria: Denial of the consensus to use individual clinical data for research purposes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: COMPACS|We will modify the current version of the COMPACS software package to implement several guideline-derived algorithms to help the clinician to reduce diagnostic errors and increase the adherence to current guidelines|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inconsistencies between quantitative and qualitative parameters in the report | Number of inconsistencies between quantitative and qualitative parameters in the report | During analysis of echocardiographic data | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inconsistencies between the clinical diagnosis and clinical guidelines | Number of inconsistent clinical diagnoses in the report and indications included in current guidelines | During analysis of echocardiographic data | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transthoracic echocardiography, Transesophageal echocardiography, Report
Dermatitis Herpetiformis Refractory to Gluten Free Diet

Study Overview
=================
Brief Summary
-----------------
The main purpose of the study is to find out the natural course of refractory dermatitis herpetiformis and the development of possible complications the strictness of gluten-free diet treatment in refractory dermatitis herpetiformis

Detailed Description
-----------------
Refractory dermatitis herpetiformis refers to dermatitis herpetiformis unresponsive to gluten-free diet therapy. So far, there is very little knowledge on the course of the disease and the causes and prognosis of refractory celiac disease. Study patients with refractory dermatitis herpetiformis will be recruited. As a control material dermatitis herpetiformis patients with good response to gluten-free dietary treatment will be recruited.

Official Title
-----------------
Gluteenittomaan Ruokavaliohoitoon Vastaamaton Ihokeliakia

Conditions
-----------------
Dermatitis Herpetiformis

Intervention / Treatment
-----------------
* Other: Assessment of prognosis of refractory dermatitis herpetiformis. No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Study patients: Dermatitis herpetiformis diagnosis Dermatitis herpetiformis rash not responding to a strict gluten-free diet after at least 3 years Control patients: Dermatitis herpetiformis diagnosis Dermatitis herpetiformis with good response to a gluten-free diet Exclusion Criteria: Study patients: -Not following strict gluten-free diet Control patients: -Not following a strict gluten-free diet

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Refractory dermatitis herpetiformis patients<br>Dermatitis herpetiformis rash not controlled by strict glute-free diet | Other: Assessment of prognosis of refractory dermatitis herpetiformis. No intervention<br>* Assessment of prognosis of refractory dermatitis herpetiformis. No intervention<br>|
| Dermatitis herpetiformis patients with good response to gluten-free diet<br>Dermatitis herpetiformis rash controlled by strict glute-free diet | Other: Assessment of prognosis of refractory dermatitis herpetiformis. No intervention<br>* Assessment of prognosis of refractory dermatitis herpetiformis. No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical prognosis | Occurrence of complications | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dietary adherence GIP test, CDAT, TG2, TG3 and Ema antibodies, anamnesis | The strictness of gluten-free diet (GIP test) | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dermatitis herpetiformis, dapsone, gluten-free diet
A Study on the Status Quo of Physical Exercise for the Elderly

Study Overview
=================
Brief Summary
-----------------
Through interview, taking the elderly community in Beijing as an example, this study will try to further understand the current physical exercise situation of the elderly in the community, and analyze the factors influencing their participation degree. By this way, we will try to provide constructive suggestions for the development and design of universal community physical exercise programs for the elderly.

Official Title
-----------------
A Study on the Status Quo of Physical Exercise for the Elderly in Beijing Community

Conditions
-----------------
Elderly, Physical Exercise, Community

Intervention / Treatment
-----------------
* Other: questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Regardless of gender, age ≥ 65 years old Lived in Beijing for a long time Normal listening, speaking, and comprehension skills Exclusion Criteria: Accompanied by significant cognitive dysfunction Diseases that seriously affect their participation in sports, such as fractures, tumors, neurological diseases, etc.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: questionnaire|Use the Questionnaire on physical exercise of the elderly in Beijing community to collect the related information of the elderly.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| questionnaire | Use the Questionnaire on physical exercise of the elderly in Beijing community to collect the related information of the elderly. | 1 day (once) |
High Flow Nasal Cannula After Esophagectomy

Study Overview
=================
Brief Summary
-----------------
This study will compare the effect of HFNC versus standard oxygen administration after elective esophagectomy for cancer.

Official Title
-----------------
High Flow Nasal Cannula Oxygen Administration Versus Standard Care After Esophagectomy for Cancer: a Randomized Controlled Trial.

Conditions
-----------------
Esophageal Cancer, Postoperative Pulmonary Atelectasis, Postoperative Pneumonia, Postoperative Pneumothorax, Postoperative Infection of Incision, Postoperative Acute Myocardial Infarction

Intervention / Treatment
-----------------
* Device: AIRVO2
* Other: STANDARD CARE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elective esophagectomy for cancer METS≥4 AGE 18-85 Written informed consent Exclusion Criteria: ASA>3 COPD≥ III stage according to GOLD criteria FEV1<50% EF<30% NYHA>2 BMI<17 or >35 Kg/m2 CKD with eGFR<60 mL/min

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HFNC<br>Administration of high flow nasal oxygen after extubation for 48 hours | Device: AIRVO2<br>* APPLICATION OF HIGH FLOW NASAL CANNULA OXYGEN FOR 48 HOURS AFTER ESOPHAGECTOMY<br>|
| Other: STANDARD OXYGEN<br>Administration of oxygen through standard devices (nasal cannulae, venturi mask, none) | Other: STANDARD CARE<br>* APPLICATION OF OXYGEN THROUGH STANDARD CARE FOR 48 HOURS AFTER ESOPHAGECTOMY<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| POST-OPERATIVE PULMONARY COMPLICATIONS | Describe the frequency of PPC that include: pneumonia, pleural effusion, pneumothorax, atelectasis, ARDS, aspiration pneumonia, trachea-bronchial lesion, air leak | within 30 days after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CARDIO-VASCULAR COMPLICATIONS | Describe the frequency of myocardial infarction, pulmonary edema, cardiac arrest, pulmonary embolism, deep venous thrombosis, stroke, pericardtis | within 30 days after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
esophageal cancer, anesthesia, high flow nasal cannula, pneumonia, esophagectomy, acute myocardial infarction
Expressiona and Diagnostic Potential of miRNAs in NSCLC

Study Overview
=================
Brief Summary
-----------------
Its to explore the expression pattern, diagnostic and prognostic potentials of miRs (106b-5p, 601 and 760) in serum of NSCLC patients

Detailed Description
-----------------
A retrospective observational study on NSCLC patients, to determine the serum expression levels if some miRNAs in NSCLC patients and to find if having proper diagnostic and prognostic values in early disease detection, and/or staging.

Official Title
-----------------
The Expression Profiling of Serum miRNAs (106b-5p, 601, and 760) in Non-small Cell Lung Cancer Patients

Conditions
-----------------
Non Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: First time and recently diagnosed NSCLC patient Exclusion Criteria: Recurrent NSCLC Start of chemotherapy, radiotherapy or surgical intervention Previous treatment Cancer history

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| NSCLC patients<br>Patients were diagnosed with NSCLC at any stage, then will be subdivided into Early stage, Lympho-node involvement stage and Distant metastatic stage | Other: No intervention<br>* No intervention<br>|
| Control subjects<br>Appearantly healthy age-matched individuals | Other: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of the expression | Expression profiling of the selected miRNAs | By the end of the study (September 2022) |
THA With and Without Computer Navigation

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to compare postoperative results between patients who had total hip arthroplasty (THA) with and without the use of a computer navigation program. The main questions this study aims to answer are: Can using computer navigation produce better THA implant placement? Can using computer navigation make surgery more efficient? Participant data collected include their postoperative x-rays and total operative time.

Detailed Description
-----------------
The goal of this retrospective study is to compare implant placement and operative time of patients who underwent direct anterior total hip arthroplasty with and without the use of a computer navigation program. X-rays are used to measure acetabular cup orientation, leg length discrepancy, and total operative time.

Official Title
-----------------
The Use of Intraoperative Fluoroscopic Computer Navigation on Hip Arthroplasty Component Position

Conditions
-----------------
Hip Osteoarthritis, Avascular Necrosis of Hip

Intervention / Treatment
-----------------
* Procedure: Intraoperative Fluoroscopic Computer Navigation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who underwent Direct Anterior (DA) THA with the principal investigator between August 2018 and February 2020 and received ACTIS stem and PINNACLE cup with or without computer navigation Exclusion Criteria: Patients who underwent subsequent revision THA, conversion arthroplasty, hybrid procedures, experienced native or postoperative dislocations, and missing or inadequate radiographs at time of data collection.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Traditional Overlay<br>Subjects who underwent THA without use of computer navigation | |
| Computer Navigation<br>Subjects who underwent THA with use of computer navigation | Procedure: Intraoperative Fluoroscopic Computer Navigation<br>* Computer technology used during surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cup inclination | Acetabular cup orientation | 12 weeks post op | 
| Cup anteversion | Acetabular cup anteversion | 12 weeks post op | 
| Leg length discrepancy | Leg length discrepancy | 12 weeks post op | 
| Operative time | Operative time in minutes | Immediate post op | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
total hip arthroplasty, computer navigation